Introduction
Prior to Programmed Death 1 (PD1) and Programmed Death Ligand 1 (PDL1) immune checkpoint inhibitors development, Non Small Cell Lung Cancer (NSCLC) stage IV patients faced a grim prognosis following resistance to platinum based chemotherapy. Standard second line treatment options included Docetaxel (1), Pemetrexed (2) or Epidermal growth factor tyrosine kinase inhibitors (3, 4) and median overall survival did not exceed 8 months, at the expense of significant toxicity.
PD1 and PDL1 inhibitors changed all of that in several pivotal trials. Nivolumab, a human IgG4 programmed death 1 immune checkpoint inhibitor antibody, is now approved in Israel as well as other parts of the world, for the treatment of patients with advanced NSCLC and disease progression despite platinum-based chemotherapy, without a need to determine the level of PD-L1 expression in the tumor. The CheckMate 057 trial enrolled 582 patients who were randomized to receive Nivolumab or Docetaxel. Nivolumab demonstrated improved overall survival (OS) compared with Docetaxel with a hazard ratio (HR) of 0.73 (P=.0015), and a median OS of 12.2 months in patients treated with Nivolumab compared with 9.4 months in patients treated with Docetaxel (5, 6) .
In this article, we retrospectively analyzed the results of treating NSCLC patients with Nivolumab. This real lifedata represents, the outcome of a compassionate use program, utilizing broad inclusion criteria.
Patients and methods

Patients.
A retrospective analysis was carried out in a thoracic oncology service in a tertiary referral center (Tel-Aviv Sourasky Medical Center), on patients with NSCLC, both squamous and non-squamous subtypes. All patients were treated with Nivolumab as part of a generous compassionate use program supported by BMS.
Inclusion criteria were patients with documented NSCLC, and a performance status of Eastern Cooperative Oncology Group (ECOG) 0-4. The cohort included both positive and negative pdl1 tumors, as well as any EGFR/ALK/ROS1 mutation status. Treatment by nivolumab. A total number of 838 Nivolumab doses were administered (range: 1-41, median 7). Treatment was discontinued due to progressive disease (PD) in 46 (59.7%) patients, toxicity in 5 (6.5%), complete response (CR) in 1 (1.3%), death in 15 (19.5%), serious adverse events in 2 (2.6% stroke in one, sepsis in one) and consent withdrawal in one (1.3%). Seven patients remain on the drug. Nivolumab was given as the 1st line of treatment in 4% (elderly patients with good performance status, in whom chemotherapy was not an option), second line in 56%, third line in 18%, fourth in 17%, and fifth in 5% of the patients.
Toxicity of nivolumab.
Reported side effects were fatigue, rash, arthralgia, pruritus, diarrhea, nausea, loss of appetite, abdominal pain and pneumonitis. The most common was fatigue, documented in 52 patients. Side effects requiring steroids were diarrhea (10/15 patients) and pneumonitis (5/5 patients), only one pneumonitis patient had to stop treatment. Endocrinopathy, mostly hypothyroidism, was observed in 10 patients.
Response to nivolumab.
Response assessment was performed in the 62 patients who got at least four cycles of Nivolumab.
There was CR in 1 patient, partial response in 11, stable disease in 25 and PD in 25. The observed response rate was 19%. The disease control rate was 60%. Median progression free survival (mPFS) from the first dose to treatment interruption was 4 months. The PFS curve is depicted in Fig. 1 . Survival data was analyzed after 22 months of follow-up. The overall survival was 34.9%, while PFS was 19.3%. Median overall survival from the first dose given and until patient's death or last follow up is 8 months. The OS curve is shown in Fig. 1 . PFS and OS were similar for elderly vs. young patients (cut-off age 65), female vs. male sex, ECOG 1 vs. higher and early (1-2) vs. late line of treatment. All failures of Nivolumab occurred within the first 12 months of administration.
Discussion
Our results reflect real-life data on non-selected, PDL1 status unknown patients, including 48% patients with ECOG PS of 2 and 3, and including 41% heavily pretreated patients. Yet, the results are similar to and even better than those seen in the already published RCT's, with ORR of 19% and median 22-months-survival of 34.9%. We could not isolate any characteristics that can predict who will benefit from immunotherapy. Side effects were almost always mild, and required discontinuation of treatment in less than 4% of patients.
Nivolumab was superior to Docetaxel in OS as well as side-effects profile, regardless of PDL1 status, in two RCT's. Checkmate 017 (7) was conducted on 272 patients with squamous cell histology, and showed mOS to be 9.2 months with Nivolumab, compared to 6 months with Docetaxel (HR, 0.59). Checkmate 057 (5) was performed on 582 patients with non-squamous histology, and again demonstrated superior OS of Nivolumab vs. Docetaxel (12.2 vs. 9.4 months; HR, 0.73).
Another PD1 inhibitor antibody, Pembrolizumab, was also superior to Docetaxel in a phase III trial. Keynote-010 (8) randomized 1,034 patients with NSCLC (all histology types) and at least 1% PDL1 expression, into either Pembrolizumab or Docetaxel treatment. The antibody resulted in significantly better OS (10.4 months and 12.7 months for both Pembrolizumab groups vs. 8.5 months, HR 0.71 and 0.61 respectively). Among patients with pdl1 expression above 50% OS reached an unprecedented 17.3 months. PDL1 antibodies showed superiority over Docetaxel as well. Atezolizumab was tested in OAK trial (9) , which randomized 1,225 patients with NSCLC (all histology types). OS was prolonged regardless of PDL1 expression (13.8 vs. 9.6 months, HR 0.73), while patients with ≥1% expression reached mOS of 15.7 months.
All immune checkpoint inhibitors were found to be less toxic than chemotherapy. All exhibited ORR of 14-20% with a median duration response of 16-20 months. Evidence is beginning to emerge regarding efficacy after longer follow-up. Gettinger et al described median 2-year-OS of 24% and median 3-year-OS of 18% in Nivolumab phase I expansion cohort (10) . Brahmer et al presented as yet unpublished results of phase I Nivolumab in NSCLC, with an impressive median 5-year-OS of 16% (11) . Unpublished results were also presented of 2-year-OS of 29 and 23% from Checkmate 057 and Checkmate 017, respectively (12) .
In conclusion, Nivolumab is active and well tolerated in patients with NSCLC. This is based on highly selected population accrued for clinical trials and on non-selected cohorts reflecting daily service in thoracic oncology units. Our real-life data supports the results achieved in clinical trials, and supply a solid ground for continuing the use of Nivolumab in chemotherapy-pretreated patients with advanced disease.
